翰宇药业(300199) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥141,551,103.90, a decrease of 42.77% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥91,457,450.95, representing a decline of 1,138.54% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was -¥91,096,260.95, a decrease of 37,569.70% compared to the previous year[5]. - Total operating revenue for the current period is ¥507,727,212.06, a decrease of approximately 26.2% compared to ¥687,479,488.97 in the previous period[36]. - Net profit for the current period is -¥117,633,535.52, compared to a net profit of ¥55,870,023.74 in the previous period, indicating a significant decline[39]. - Basic and diluted earnings per share for the current period are both -¥0.13, compared to ¥0.06 in the previous period[42]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,828,446,770.07, down 4.77% from the end of the previous year[5]. - The company's total assets decreased from RMB 4,020,327,051.30 at the end of 2020 to RMB 3,828,446,770.07, a decline of about 4.8%[34]. - Total liabilities decreased from RMB 2,342,419,871.59 at the end of 2020 to RMB 2,245,469,392.00, a reduction of approximately 4.1%[32]. - The company's long-term borrowings increased significantly from RMB 645,509,964.92 at the end of 2020 to RMB 1,087,740,990.19, an increase of about 68.4%[32]. - The company's total equity attributable to shareholders decreased from RMB 1,637,566,298.59 to RMB 1,528,199,337.00, a decline of approximately 6.7%[34]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥129,767,232.40, an increase of 272.30% year-on-year[14]. - Cash inflow from operating activities totaled ¥699,261,065.58, down from ¥731,773,408.25 in the previous period, reflecting a decrease of approximately 4.4%[43]. - The net cash flow from operating activities increased to ¥129,767,232.40, compared to ¥34,855,618.27 in the previous period, reflecting a significant improvement[46]. - Total cash outflow from operating activities was ¥569,493,833.18, down from ¥696,917,789.98, indicating a reduction in operational cash expenses[46]. - The net cash flow from investing activities was -¥175,082,526.87, compared to -¥165,384,845.11, showing an increase in cash outflow for investments[46]. - Cash inflow from financing activities rose to ¥1,365,284,136.16, up from ¥806,090,571.30, indicating stronger financing efforts[46]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,218[17]. - Major shareholder Zeng Shaogui holds 16.75% of shares, totaling 153,606,167 shares, with 149,973,186 shares under lock-up[17]. - Major shareholder Zeng Shaoqiang holds 11.67% of shares, totaling 107,047,840 shares, with all shares under lock-up[17]. - The company has a significant number of shares pledged by major shareholders, including Zeng Shaogui and Zeng Shaoqiang[17]. - The company has a total of 6.07% of shares held by Shenzhen Investment Control Capital, indicating strong institutional interest[17]. Product Development and Approvals - The company has received approval for the consistency evaluation of several products, including Carboprost Injection and Thymosin Alpha1 Injection, indicating successful quality and efficacy assessments[22]. - The company announced that the product Pramipexole Hydrochloride Sustained-Release Tablets has been approved for listing, which is considered equivalent to passing the consistency evaluation[24]. - The company is actively expanding its product portfolio with new approvals and consistency evaluations, enhancing its market position[22]. Governance and Compliance - The company is focused on maintaining strong governance with major shareholders being current directors, ensuring alignment of interests[20]. - The company has not audited its third-quarter report, which may affect the reliability of the financial data presented[59]. - The company adjusted its financial statements due to the first-time implementation of new leasing standards, impacting the balance sheet[49].